Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy

An experimental Alzheimer’s drug and its designer are getting a second chance.
On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

As psychedelics near approval, there’s no consensus on how they work

DENVER — The founder of Field Trip, a chain of shuttered ketamine clinics currently facing insolvency, put forward an unexpected theory of how psychedelics work

July 3, 2023

Gilead’s newest acquisition: a liver disease drug with $1B in peak sales potential

Gilead’s acquisition of CymaBay Therapeutics underscores the company’s historic success in liver diseases and could bring in $1 billion in peak annual sales. Gilead announced

February 13, 2024

AGEPHA Pharma’s LODOCO receives US FDA approval

LODOCO is indicated for reducing the risk of stroke, myocardial infarction and cardiovascular death in adult ASCVD patients. Credit: AGEPHA Pharma/ Business Wire. AGEPHA Pharma

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.